PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 4, 2026Journal of Clinical Oncology0 citations

Ultra-Hypofractionated Radiotherapy and Oral Relugolix for Intermediate Risk Prostate Cancer

Ultra-hypofractionated radiotherapy and concomitant oral relugolix for treatment of intermediate risk prostate cancer (ULTRA-HERO).

View Full Paper

Authors

GFGiulio FrancoliniFAFilippo AlongiAAAndrea Gaetano Allegra

Discussion

Loading...

Member takes

Overview

Prospective trial evaluates biochemical response in prostate cancer with concurrent ultrahypofractionated radiotherapy and relugolix, suggesting improved outcomes.

Key Points

  • The study aims to evaluate the effectiveness of combining short-course oral relugolix with ultrahypofractionated radiotherapy in intermediate-risk prostate cancer patients.
  • Prospective, single-arm Phase II trial design.
  • Participants: patients with unfavorable intermediate risk prostate carcinoma.
  • Treatment: 36.25 Gy in 5 fractions of ultrahypofractionated radiotherapy accompanied by short-course oral relugolix.
  • Oral relugolix dosed at 360 mg for an attack dose, followed by 120 mg daily for 6 months.
  • Primary endpoint: rate of complete biochemical response measured at 6 months post-treatment.
  • Enrollment of 20 patients initiated in May 2025, with a goal of 73 patients.
  • Expected proportion of patients with complete biochemical response aimed at <0.5 ng/ml at 6 months.
  • Intervention anticipated to yield improved testosterone recovery compared to historical treatments.
Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Francolini et al. (2026) studied this question.

synapsesocial.com/papers/69a7cce8d48f933b5eed8d05https://doi.org/10.1200/jco.2026.44.7_suppl.tps411
Ask AI
Helpful
Bookmark
Share
View Full Paper